Targeted therapy reactivates 'guardian of the genome' in resistant cancer

It is common for cancer cells to find some way to disarm p53, also known as 'guardian of the genome' due to its action in preventing defective cells from dividing. 'The critical importance of the protective function of p53 is underscored by the diversity of molecular strategies employed by cancer cells to subvert p53 activity, such as overexpression of antagonistic proteins like HDM2 and HDMX,' explains senior study author Dr Loren D. Walensky from Harvard Medical School. 'Restoration of p53 activity remains an important goal in the quest for more effective cancer therapeutics.'...

Read the whole article on

More from